Table 1 –
Overall cohort demographics broken down by assay success (≥1 CTC copy number profile generated for CTCs and clinical report generated for tissue)
| CTC success | Tissue success |
Concordance cohort |
All patients | ||
|---|---|---|---|---|---|
| Sample size (n) | 115(83) | 107 (78) | 91 (66) | 138 (100) | |
| Age (yr) | 68 (62–74) | 68(62–74) | 68 (62–74) | 67(62–74) | |
| Laboratory assessments | PSA (ng/dl) | 28.5 (6.5–166.5) | 34.2 (7.7–152.1) | 32.3 (7.3–165.5) | 28.2 (7.5–151.1) |
| ALP (U/l) | 121 (76–215) | 112 (75–182) | 112 (74–192) | 117 (76–190) | |
| LDH (U/l) | 246 (201–305) | 236 (201–324) | 247 (203–329) | 238 (194–305) | |
| Treatment exposures | Prior mCRPC Tx line | 1 (0–2) | 1 (0–2) | 1 (0–2) | 1 (0–2) |
| Prior ARSi (n) | 73 (64) | 73 (68) | 62 (68) | 85 (62) | |
| Prior taxane (n) | 33 (29) | 35 (33) | 30 (33) | 38 (28) | |
| Disease compartments with metastasis | Bone (n) | 93 (81) | 82 (77) | 69 (76) | 112 (81) |
| Bone only (n) | 17 (15) | 10 (9.3) | 4 (4.4) | 19 (14) | |
| LN (n) | 89 (77) | 86 (80) | 72 (79) | 107 (78) | |
| Liver (n) | 24 (21) | 26 (24) | 23 (25) | 29 (21) | |
| Lung (n) | 11 (9.6) | 11(10) | 9 (9.9) | 13 (9.4) | |
| Prostate/other (n) | 31 (27) | 30 (28) | 27 (289) | 35 (25) | |
| Biopsy site | Bone (n) | 30 (26) | 19 (18) | 15 (17) | 38 (28) |
| LN (n) | 55 (48) | 56 (52) | 48 (53) | 64 (46) | |
| Liver (n) | 17 (15) | 20 (19) | 17 (19) | 22 (16) | |
| Lung (n) | 5 (4.3) | 4 (3.7) | 4 (4.4) | 5 (3.6) | |
| Prostate/other (n) | 8 (7.0) | 8 (7.5) | 7 (7.7) | 9 (6.5) |
ALP = alkaline phosphatase; ARSi = androgen receptor signaling inhibitor; CTC = circulating tumor cell; LDH = lactate dehydrogenase; LN = lymph node; mCRPC = metastatic castration-resistant prostate cancer; PSA = prostate-specific antigen; Tx = treatment.
Statistics shown are median (interquartile range) for continuous variables and count (%) for discrete variables.